Short answer
Rapport Therapeutics, Inc. (RAPP) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$27M
- −53.5% YoY · −0.7% QoQ
- EPS (diluted)
- −$0.71
- −125.7% YoY · +6.6% QoQ
Source: XBRL data from the Rapport Therapeutics, Inc. (RAPP) Q3 2025 10-Q on SEC EDGAR. USD.
Rapport Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New clinical hold risk on RAP-219 diabetic peripheral neuropathic pain trial triggered by FDA request for protocol amendments in Q4 2024
- Updated financial risk: net losses increased to $77.7M for nine months ended Sept 2025 from $58.3M in prior year, cash $513M funding through H2 2029
- Most impactful regulatory risk: FDA clinical hold on RAP-219 and uncertainty on lifting timing may delay Phase 2 development or halt program
- Operational risk: RAP-219 Phase 3 trials initiation expected Q3 2026; delays or failures may materially affect near-term development progress
- Financial risk: up to $116M contingent milestones payable to Janssen under license may require dilution, debt, or use of cash reserves
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Rapport Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.